1. Home
  2. EIC vs ZBIO Comparison

EIC vs ZBIO Comparison

Compare EIC & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • ZBIO
  • Stock Information
  • Founded
  • EIC N/A
  • ZBIO 2019
  • Country
  • EIC United States
  • ZBIO United States
  • Employees
  • EIC N/A
  • ZBIO N/A
  • Industry
  • EIC Finance/Investors Services
  • ZBIO
  • Sector
  • EIC Finance
  • ZBIO
  • Exchange
  • EIC Nasdaq
  • ZBIO NYSE
  • Market Cap
  • EIC 287.1M
  • ZBIO 268.7M
  • IPO Year
  • EIC 2019
  • ZBIO 2024
  • Fundamental
  • Price
  • EIC $14.94
  • ZBIO $8.33
  • Analyst Decision
  • EIC Strong Buy
  • ZBIO Strong Buy
  • Analyst Count
  • EIC 1
  • ZBIO 6
  • Target Price
  • EIC $17.50
  • ZBIO $31.83
  • AVG Volume (30 Days)
  • EIC 301.0K
  • ZBIO 129.7K
  • Earning Date
  • EIC 02-20-2025
  • ZBIO 05-16-2025
  • Dividend Yield
  • EIC 16.42%
  • ZBIO N/A
  • EPS Growth
  • EIC N/A
  • ZBIO N/A
  • EPS
  • EIC 1.97
  • ZBIO N/A
  • Revenue
  • EIC $46,223,036.00
  • ZBIO $5,000,000.00
  • Revenue This Year
  • EIC $39.61
  • ZBIO N/A
  • Revenue Next Year
  • EIC $27.28
  • ZBIO N/A
  • P/E Ratio
  • EIC $7.44
  • ZBIO N/A
  • Revenue Growth
  • EIC 72.79
  • ZBIO N/A
  • 52 Week Low
  • EIC $14.56
  • ZBIO $5.83
  • 52 Week High
  • EIC $16.75
  • ZBIO $26.25
  • Technical
  • Relative Strength Index (RSI)
  • EIC 35.23
  • ZBIO N/A
  • Support Level
  • EIC $14.51
  • ZBIO N/A
  • Resistance Level
  • EIC $16.05
  • ZBIO N/A
  • Average True Range (ATR)
  • EIC 0.27
  • ZBIO 0.00
  • MACD
  • EIC -0.09
  • ZBIO 0.00
  • Stochastic Oscillator
  • EIC 27.99
  • ZBIO 0.00

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.

About ZBIO ZENAS BIOPHARMA INC

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Share on Social Networks: